HHQ16 | MedChemExpress (MCE)
HHQ16 is an orally active derivative of Astragaloside IV (HY-N0431). HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling[1].
| Trivial name | HHQ16 |
| Catalog Number | HY-160706 |
| Research Area | Cardiovascular Disease |
| CAS# | 2620471-66-9 |
| Purity | ≥98.0% |
| SMILES | C[C@@]12[C@](C[C@H](O)[C@]2([H])[C@]3(C)O[C@H](C(C)(C)O)CC3)(C)[C@]4([H])C[C@H](O)[C@@]5([H])C(C)(C)C(F)(F)CC[C@]5(C6)[C@]46CC1 |
| Size | 1 mg |
| Supplier Page | https://www.medchemexpress.com/hhq16.html |